Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10764
Full metadata record
DC FieldValueLanguage
dc.contributor.authorScheffer, Ingrid Een
dc.contributor.authorZhang, Yue-Huaen
dc.contributor.authorJansen, Floor Een
dc.contributor.authorDibbens, Leanne Men
dc.date.accessioned2015-05-16T00:18:56Z
dc.date.available2015-05-16T00:18:56Z
dc.date.issued2009-02-08en
dc.identifier.citationBrain & Development 2009; 31(5): 394-400en
dc.identifier.govdoc19203856en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10764en
dc.description.abstractDravet syndrome and genetic epilepsy with febrile seizures plus (GEFS+) can both arise due to mutations of SCN1A, the gene encoding the alpha 1 pore-forming subunit of the sodium channel. GEFS+ refers to a familial epilepsy syndrome where at least two family members have phenotypes that fit within the GEFS+ spectrum. The GEFS+ spectrum comprises a range of mild to severe phenotypes varying from classical febrile seizures to Dravet syndrome. Dravet syndrome is a severe infantile onset epilepsy syndrome with multiple seizure types, developmental slowing and poor outcome. More than 70% of patients with Dravet syndrome have mutations of SCN1A; these include both truncation and missense mutations. In contrast, only 10% of GEFS+ families have SCN1A mutations and these comprise missense mutations. GEFS+ has also been associated with mutations of genes encoding the sodium channel beta 1 subunit, SCN1B, and the GABA(A) receptor gamma 2 subunit, GABRG2. The phenotypic heterogeneity that is characteristic of GEFS+ families is likely to be due to modifier genes. Interpretation of the significance of a SCN1A missense mutation requires a thorough understanding of the phenotypes in the GEFS+ spectrum whereas a de novo truncation mutation is likely to be associated with a severe phenotype. Early recognition of Dravet syndrome is important as aggressive control of seizures may improve developmental outcome.en
dc.language.isoenen
dc.subject.otherBrain Chemistry.geneticsen
dc.subject.otherEpilepsies, Myoclonic.genetics.metabolism.physiopathologyen
dc.subject.otherEpilepsy, Generalized.genetics.metabolism.physiopathologyen
dc.subject.otherGenetic Predisposition to Disease.geneticsen
dc.subject.otherHumansen
dc.subject.otherInfanten
dc.subject.otherMutation, Missense.geneticsen
dc.subject.otherNAV1.1 Voltage-Gated Sodium Channelen
dc.subject.otherNerve Tissue Proteins.geneticsen
dc.subject.otherReceptors, GABA-A.geneticsen
dc.subject.otherSeizures, Febrile.genetics.metabolism.physiopathologyen
dc.subject.otherSodium Channels.geneticsen
dc.subject.otherSyndromeen
dc.subject.otherVoltage-Gated Sodium Channel beta-1 Subuniten
dc.titleDravet syndrome or genetic (generalized) epilepsy with febrile seizures plus?en
dc.typeJournal Articleen
dc.identifier.journaltitleBrain & developmenten
dc.identifier.affiliationDepartment of Medicine, The University of Melbourne, Austin Health, Victoria, Australiaen
dc.identifier.doi10.1016/j.braindev.2009.01.001en
dc.description.pages394-400en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/19203856en
dc.type.austinJournal Articleen
local.name.researcherScheffer, Ingrid E
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.languageiso639-1en-
item.cerifentitytypePublications-
crisitem.author.deptEpilepsy Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Dec 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.